

Innovation Meets Compassion: Lysando and Bamberg UA Collaborate to Tackle Antibiotic Resistance in Ukrainian Hospitals with Medolysin[®] Donation

TRIESENBERG, Liechtenstein, 13. November 2023 – Lysando, a pioneering biotechnology company specializing in advanced antimicrobial technology, has taken a decisive step in addressing Ukraine's escalating antibiotic-resistant bacteria crisis by teaming up with the Non-Profit Organization Bamberg UA. In a generous initiative, Lysando is donating its innovative product, Medolysin[®], to Ukrainian hospitals, offering an effective solution to combat antibiotic-resistant bacteria in wound care.

At the heart of this collaborative effort is Leonhard Stärk, an esteemed member of Lysando's Ethics Committee and former State Chairman (Ex-Landesvorsitzender) of the Bavarian Red Cross. His support has been pivotal in making this initiative possible.

The current crisis in Ukraine has brought to light a perilous threat — highly resistant bacteria that challenge even the most potent antibiotics. Conventional treatments have proven ineffective, causing deep concern among healthcare professionals and researchers. In a recent report by Lund University, Prof. Kristian Riesbeck, professor of Clinical Bacteriology, underscored the severity of the situation, noting — “... I must admit that I have never encountered bacteria as resistant as this before”.

Count Markus Matuschka de Greiffenclau, Chairman of the Board of Directors at Lysando, expressed his concern, stating, “With the dramatic rise of wound infections caused by highly antibiotic-resistant bacteria, many Ukrainian soldiers face the risk of developing sepsis, with amputation being their only remaining curative option. Leveraging the power of AI, Lysando has developed a ground-breaking technology named Artilysin[®] which successfully combats antibiotic-resistant bacteria and accelerates healing. By generously donating Medolysin[®] Wound spray to Ukrainian hospitals, the team at Lysando aims to prevent amputations and enable wounded servicemen and women to make a full recovery.”

Non-Profit Organization Bamberg UA plays a crucial role in this collaboration, facilitating the distribution of Medolysin[®] Wound Spray to Ukrainian hospitals. Our shared goal is to ensure that no one in Ukraine faces the grim prospect of amputation when hope and healing are within reach. This collaboration embodies the power of humanity, compassion, and cutting-edge innovation.

Medolysin[®] was produced at Lysando's state-of-the-art R&D and production center, Lysando Innovations Lab, located within the Regensburg BioPark.

About Lysando AG

Lysando AG is the market leader for antimicrobial proteins, so-called Artilysin[®] molecules. They can effectively eliminate problem-causing bacteria without associated high risk of resistance formation and microbial disbalances. Artilysin[®] constitutes an innovative, proprietary, and environmentally friendly technology with a wide range of applications.